Vikas Shah - GOV UK gov.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gov.uk Daily Mail and Mail on Sunday newspapers.
Credit: ESMO credit
Lugano, Switzerland; Denver, CO, USA, 11 March 2021 - The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) have the pleasure of announcing that the Heine H. Hansen Award 2021 is conferred on Johan Vansteenkiste, Professor of Medicine at the Catholic University of Leuven and Head of Clinic in the Respiratory Oncology Unit and its Clinical Trial Unit at University Hospitals Leuven. An internationally renowned clinical researcher and devoted educator in the field of lung cancer, Vansteenkiste will have the opportunity to give an award lecture at the upcoming European Lung Cancer Virtual Congress (ELCC) 2021. (1, 2, 3) The event will also feature the lecture of the 2020 award recipient Fiona Blackhall, Professor of Thoracic Oncology at Manchester Cancer Research Centre, University of Manchester, and Honorary Consultant in Medical Oncology at The Christie NHS Foundation Trust. (4) The Heine H. Hansen A
Share
A new research development from The University of Manchester and the Christie NHS Foundation Trust has shown progress for developing a potential new cancer treatment using high energy electron beams.
The collaborative research team have published their findings in Nature’s journal, Scientific Reports, and demonstrated that Very High Energy Electron (VHEE) beams can have a positive effect for treatment with damage to DNA at similar levels to those conventional X-Rays and proton therapy, whilst harnessing the unique technological qualities of electron beams.
Human cells are composed of DNA and this new result is a fundamental step forward for VHEE radiation as a treatment for a number of cancers. This new treatment has the potential to extend conventional treatment with electron beams used in hospital which only penetrate a few centimetres into the body and struggle to reliably reach deep seated tumours.
Research at The University of Manchester has made a significant impact nationally and internationally on improving the outcome for children with acute lymphoblastic leukaemia (ALL). Survival rates of children with ALL in the west have risen from 60% to 90%, though in countries with limited resources ALL continues to be a fatal disease. Globally, the survival rate for children with ALL is around 40%.
Professor Vaskar Saha has helped to increase survival rates by 10% in the UK and in India. By linking five major paediatric centres, he has created a national hub of cancer centres which work together to agree standards of care based on the principles of the NHS. They have implemented agreed, uniform standards of care and treatment across all of the treatment centres and formed the Indian Childhood Collaborative Leukaemia (ICiCLe) group.